Cerebral malaria (CM) is a serious complication of Plasmodium falciparum infection associated with cerebral vasculopathy, high mortality, and risk of neurological sequelae. In human CM, infected RBCs adhere to the brain endothelium and occlude the cerebral blood vessels causing cerebral vascular damage, impaired perfusion, vasospasms, vasoconstriction, and inflammation. Vasoactive factors, including endothelin (ET-1), have become increasingly important in the pathogenesis of CM. We previously demonstrated that antagonism of the ET-1 type A receptor (ETA) improved survival and attenuated brain hemorrhage in murine CM. In this study we tested the hypothesis that ET-1 contributes to CNS inflammation and BBB disruption in experimental CM (ECM) via its actions on ETA. To test this hypothesis we used our model of Plasmodium berghei ANKA (PbA) infection of C57BL/6 mice. PbAinfection resulted in activation of monocytic CNS cells, microglia, which are important in inflammation. ECM was also associated with an increase in brain microvascular endothelial cell activation which is critical for leukocyte adhesion. Treatment of PbA-infected mice with ETA receptor antagonists attenuated the increase in microglial and endothelial cell activation, suggesting that ET-1 contributes to CNS inflammation during ECM. Furthermore, leakage of Evans blue bound-albumin into the brain was reduced in ECM mice receiving ETA receptor antagonism, providing further support that disruption of the BBB and inflammation during ECM result, in part, from increases in ET-1 and its actions on the ETA receptor. Together these findings illustrate a role for ET-1 in the immunopathology and vasculopathy associated with ECM, and highlight the peptide as a potential target for adjunctive therapy for the protection of neurological function in patients with CM. Sepsis, a heterogeneous class of syndromes, is associated with the development of progressive damage in multiple organs. The pathogenesis of sepsis-induced myocardial dysfunction is still not fully understood. The present study examined the alteration of key angiogenic signaling pathway mediated by the vascular endothelial growth factor (VEGF) in sepsis heart and the effects of dual endothelin (ET) antagonism on it. Normal male Wistar rats at age 8 wks were administered with lipopolysaccharide (LPS: 15 mg/kg) and then sacrificed at different time points (1 h, 3 h, 6 h and 10 h). Some rats without LPS administration was considered as the control group. Some of the LPS-administered rats were treated with dual endothelin blocker (SB209670, 1 mg/kg body weight) for 6 h and then sacrificed. Administration of LPS resulted in increases in the serum levels of TNF-alpha (maximum at 1 h after LPS, 1200-fold compared to control rats), and ET-1 (maximum at 3 h after LPS, 25-fold compared to control rats). At 6 h after LPS administration, we found decreased percent of fractional shortening in the heart. The expression of VEGF, and its downstream angiogenic signaling molecules namely eNOS and NO, was significantly increased in heart tissues after LPS administration compared to the control group which was also accompanied by increased cardiac ET-1 level. Dual endothelin blockade for 6 h further upregulated the VEGF angiogenic signaling in endotoxemic heart. Purpose: Endothelin-1 (ET-1) is overexpressed in breast carcinomas, while circulating levels of its precursor (Big ET-1) have also been found elevated. In the present study, we evaluated plasma ET-1 0024-3205
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